Michael Morabito
Stock Analyst at Chardan Capital
(n/a)
# 4,598
Out of 4,975 analysts
11
Total ratings
9.09%
Success rate
-28.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Morabito
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKRO Akero Therapeutics | Maintains: Buy | $79 → $81 | $44.72 | +81.13% | 2 | Mar 17, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $202 → $203 | $432.53 | -53.07% | 2 | Feb 26, 2021 | |
| DRRX DURECT | Maintains: Buy | $70 → $80 | $1.91 | +4,088.48% | 2 | Feb 3, 2021 | |
| ETNB 89bio | Maintains: Buy | $59 → $95 | $8.86 | +972.23% | 3 | Sep 15, 2020 | |
| VKTX Viking Therapeutics | Maintains: Buy | $15 → $20 | $26.98 | -25.87% | 2 | Aug 31, 2020 |
Akero Therapeutics
Mar 17, 2021
Maintains: Buy
Price Target: $79 → $81
Current: $44.72
Upside: +81.13%
Madrigal Pharmaceuticals
Feb 26, 2021
Maintains: Buy
Price Target: $202 → $203
Current: $432.53
Upside: -53.07%
DURECT
Feb 3, 2021
Maintains: Buy
Price Target: $70 → $80
Current: $1.91
Upside: +4,088.48%
89bio
Sep 15, 2020
Maintains: Buy
Price Target: $59 → $95
Current: $8.86
Upside: +972.23%
Viking Therapeutics
Aug 31, 2020
Maintains: Buy
Price Target: $15 → $20
Current: $26.98
Upside: -25.87%